MAP-2 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a potent inhibitor of p38 MAPK, a pathway closely associated with MAP-2 regulation. By specifically targeting p38 MAPK, SB203580 disrupts the downstream signaling cascades that may involve MAP-2, influencing its cellular functions indirectly through modulation of the MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK1/2 inhibitor, targeting the MAPK/ERK pathway. As MAP-2 is implicated in neurite outgrowth and synaptic plasticity, inhibiting MEK1/2 with U0126 can indirectly affect MAP-2 by disrupting the MAPK/ERK signaling axis crucial for these neuronal processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 acts as a selective JNK (c-Jun N-terminal kinase) inhibitor. JNK is involved in various cellular processes, and its inhibition by SP600125 can impact MAP-2 indirectly by interfering with downstream pathways associated with JNK signaling, potentially influencing neuronal development and plasticity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective MEK inhibitor targeting the MAPK/ERK pathway. By inhibiting MEK, PD98059 disrupts the downstream signaling cascades that may involve MAP-2, influencing its cellular functions indirectly through modulation of the MAPK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K (phosphoinositide 3-kinase) inhibitor, impacting the PI3K/Akt signaling pathway. As MAP-2 is known to interact with the PI3K/Akt pathway in neuronal cells, the inhibition of PI3K by LY294002 can indirectly affect MAP-2 by disrupting signaling events associated with PI3K, potentially altering processes related to neuronal morphology and plasticity. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
AZD6244, also known as Selumetinib, is a selective MEK1/2 inhibitor targeting the MAPK/ERK pathway. By inhibiting MEK1/2, AZD6244 disrupts the downstream signaling cascades that may involve MAP-2, influencing its cellular functions indirectly through modulation of the MAPK pathway. | ||||||
JNK Inhibitor V | 345987-15-7 | sc-202672A sc-202672 | 1 mg 5 mg | $60.00 $169.00 | 3 | |
AS601245 is a JNK (c-Jun N-terminal kinase) inhibitor. JNK is involved in various cellular processes, and its inhibition by AS601245 can impact MAP-2 indirectly by interfering with downstream pathways associated with JNK signaling, potentially influencing neuronal development and plasticity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K (phosphoinositide 3-kinase), affecting the PI3K/Akt signaling pathway. Given the interaction of MAP-2 with the PI3K/Akt pathway in neuronal cells, Wortmannin's inhibition of PI3K can indirectly affect MAP-2 by disrupting signaling events associated with PI3K, potentially altering processes related to neuronal morphology and plasticity. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745 is a selective p38 MAPK inhibitor, targeting a pathway closely associated with MAP-2 regulation. By specifically inhibiting p38 MAPK, VX-745 disrupts the downstream signaling cascades that may involve MAP-2, influencing its cellular functions indirectly through modulation of the MAPK pathway. | ||||||
BIX02188 | 1094614-84-2 | sc-503854 | 10 mg | $380.00 | ||
BIX02188 is a selective MEK5 inhibitor, impacting the MAPK/ERK5 pathway. As MAP-2 is implicated in neurite outgrowth and synaptic plasticity, inhibiting MEK5 with BIX02188 can indirectly affect MAP-2 by disrupting the MAPK/ERK5 signaling axis crucial for these neuronal processes. | ||||||